Antiretroviral drugs and therapy (ART)

The United States National Institutes of Health-funded international randomized clinical trial START (Strategic Timing of Antiretroviral Treatment) has found compelling evidence that the benefits of starting antiretroviral therapy as soon as someone is diagnosed outweigh the risks of delaying.

The March 2015 meeting went beyond the usual three-year forecast by including a model of new ARVs that will be needed up to 2024.

This document presents experiences of how community-based antiretroviral therapy (ART) delivery can improve both the level of access to treatment and the quality of health outcomes for people living with HIV.

This update summarizes experiences of countries that have already begun to implement earlier treatment approaches as part of a national policy or pilot programmes.

ART is being rapidly scaled up in Myanmar, led by National AIDS Programme (NAP) and supported by many partners.

This infographic details the process for developing long-acting injectables for PrEP and treatment.

This case study describes the model and outcomes of the public private partnership (PPP) that has been implemented by the Alliance since 2009 in Yangon, Myanmar.

This fact sheet present data for 194 WHO Member States – including 138 low- and middle-income countries (LMIC) – and 35 Fast‑Track countries, respectively through July 2017.

This fact sheet present data for 194 WHO Member States – including 139 low- and middle-income countries – and 35 Fast-Track countries, respectively through November 2017.

The primary purpose of antiretroviral therapy is to keep people living with HIV in good health.